NCT02411448 · OUTCOME

Part B: Number of Participants With Anti-Ramucirumab Antibodies

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) · Source last updated 2026-01-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Cycle 1 Predose through Follow-up (Up To 37 Months)

What was measured

Part B: Number of Participants With Anti-Ramucirumab Antibodies.

Analysis population: All participants who received at least one dose of study drug. Per protocol, Part A did not evaluate Anti-Ramucirumab Antibodies .

Groups in this outcome

Part B: Ramucirumab+ Erlotinib

Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met.

Part B: Placebo+ Erlotinib

Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Part B: Ramucirumab+ Erlotinib	221
Part B: Placebo+ Erlotinib	225

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part B: Ramucirumab+ Erlotinib	14	Not reported	Not reported	Not reported	Not reported
Part B: Placebo+ Erlotinib	18	Not reported	Not reported	Not reported	Not reported

Complete source fields

calculate Pct

false

classes

categories
measurements
group Id
OG000
value
14
group Id
OG001
value
18

denoms

counts
group Id
OG000
value
221
group Id
OG001
value
225
units
Participants

description

Part B: Number of Participants With Anti-Ramucirumab Antibodies.

groups

description
Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met.
id
OG000
title
Part B: Ramucirumab+ Erlotinib
description
Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met.
id
OG001
title
Part B: Placebo+ Erlotinib

param Type

COUNT_OF_PARTICIPANTS

population Description

All participants who received at least one dose of study drug. Per protocol, Part A did not evaluate Anti-Ramucirumab Antibodies .

reporting Status

POSTED

time Frame

Cycle 1 Predose through Follow-up (Up To 37 Months)

title

Part B: Number of Participants With Anti-Ramucirumab Antibodies

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice